MRSN Profile
Mersana Therapeutics Inc (MRSN) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies to treat cancer. The company is headquartered in Cambridge, Massachusetts, and was founded in 2001.
Mersana's lead product candidate, XMT-1536, is a first-in-class antibody drug conjugate (ADC) that targets the tumor microenvironment. The drug is being developed for the treatment of patients with ovarian cancer and non-small cell lung cancer. Mersana has also developed a pipeline of other ADCs that target various cancer types.
Mersana's technology platform, known as Dolaflexin, enables the company to design and develop ADCs with improved properties compared to traditional ADCs. The Dolaflexin platform includes proprietary linkers and payloads that enable the company to precisely control the drug-to-antibody ratio (DAR), optimize pharmacokinetics, and increase potency.
Mersana has partnerships with several leading pharmaceutical companies, including Takeda, Merck, and Asana Biosciences. These collaborations provide Mersana with additional funding, expertise, and resources to develop its pipeline of ADCs.
As of February 2023, Mersana's market capitalization is approximately $558 million.
|
